Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2024-04-19 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2023年度独立董事述职报告（黄欣琪）
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report". It is a detailed report by an independent director about their duties, attendance, opinions, and activities during the year 2023. The content includes descriptions of meetings attended, opinions on company matters, oversight of financial reports, internal controls, and stock incentive plans. It is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a regulatory filing or announcement. It is a management-related report focusing on the independent director's role and activities, which fits best under the category of Board/Management Information (MANG). The document length (6448 characters) and detailed content confirm it is a substantive report, not a brief announcement or certification. Therefore, the classification is MANG with high confidence.
2024-04-19 Chinese
关于EYP-1901玻璃体内植入剂药物临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acceptance of a clinical trial application by the National Medical Products Administration (NMPA) for a drug product (EYP-1901). It details the clinical trial application status, product information, and potential impact on the company. There are no financial statements, earnings data, or management discussion of financial results. The document is an official announcement about regulatory approval status, not a financial report or management report. It is also not a voting result, board change, or legal proceeding. Given the nature of the content as a regulatory announcement about clinical trial acceptance, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-04-18 Chinese
关于股东股份质押变动的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding changes in shareholder stock pledges by a major shareholder (Ningbo Kaiming Investment Management Partnership) of Betta Pharmaceuticals Co., Ltd. It details the number of shares pledged and released, pledge terms, and risk assessments related to these pledges. There is no financial statement, earnings data, or management discussion of financial results. The document is a regulatory disclosure about share pledge changes, which fits the category of Major Shareholding Notification (MRQ) or possibly Regulatory Filings (RNS). However, since it specifically concerns changes in significant share ownership levels and pledges, it aligns best with Major Shareholding Notification (MRQ). The document length is short (2315 characters), and it is not an announcement of a report publication but a direct disclosure. Therefore, the classification is MRQ with high confidence.
2024-03-25 Chinese
关于BPI-221351片获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving clinical trial approval from the National Medical Products Administration (NMPA) for a new drug candidate (BPI-221351). It details the approval notice, the drug's research background, and potential impact on the company. The document is short (1324 characters) and serves as an official announcement of regulatory approval rather than a financial report or detailed clinical study. It does not contain financial data, management changes, or shareholder information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-03-22 Chinese
关于BPI-520105片获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving clinical trial approval from the National Medical Products Administration (NMPA) for a new drug candidate (BPI-520105). It details the approval notice, the drug's research background, and the impact on the company. The document is short (1325 characters) and serves as an official announcement of regulatory approval rather than a financial report or detailed clinical data. It does not contain financial statements, management discussion, or other report content. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-03-20 Chinese
关于股东股份质押变动的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding changes in shareholder stock pledges by a major shareholder (Ningbo Kaiming Investment Management Partnership) of Betta Pharmaceuticals Co., Ltd. It details the number of shares pledged and released, pledge ratios, pledge terms, and related risk disclosures. The document does not contain financial statements, earnings data, or management discussion of financial results. It is a regulatory disclosure about share pledge changes, which fits the category of Major Shareholding Notification (MRQ) because it involves significant share ownership and pledge status changes by a controlling shareholder. The document length is short (2226 characters) and is a direct announcement, not a report or certification. Therefore, the best classification is MRQ with high confidence.
2024-03-15 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.